A Phase I, Randomized, Double-blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous SHR0410 in Healthy Male Participants
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs SHR-0410 (Primary)
- Indications Acute pain
- Focus Adverse reactions
- Sponsors Atridia
- 25 Feb 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 21 May 2018 Status changed from not yet recruiting to recruiting.